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Abstract
The efficacy of mother-to-child placental transfer of antibodies specific to malaria blood
stage antigens was investigated in the context of placental malaria infection, taking into
account IgG specificity and maternal hypergammaglobulinemia. The impact of the resulting
maternal antibody transfer on infections in infants up to the age of 6 months was also
explored. This study showed that i) placental malaria was associated with a reduced pla-
cental transfer of total and specific IgG, ii) antibody placental transfer varied according to
IgG specificity and iii) cord blood malaria IgG levels were similar in infants born to mothers
with or without placental malaria. The number of malaria infections was negatively associ-
ated with maternal age, whereas it was not associated with the transfer of any malaria-spe-
cific IgG from the mother to the fetus. These results suggest that i) malaria-specific IgG may
serve as a marker of maternal exposure but not as a useful marker of infant protection from
malaria and ii) increasing maternal age contributes to diminishing febrile infections diag-
nosed in infants, perhaps by means of the transmission of an effective antibody response.
Introduction
During pregnancy, the sequestration of Plasmodium falciparum-infected erythrocytes in the
placenta is known to decrease maternofetal antibody exchange. Several studies have demon-
strated an association between placental malaria (PM) and decreased maternal antibody trans-
fer to the fetus, taking into account maternal antibody levels at delivery [1–3]. One of these
studies, enrolling 213 mother/child pairs in The Gambia, showed that prematurity and low
birth weight were associated with a PM-dependent decrease of Haemophilus influenzae- and
Streptococcus pneumoniae-specific antibody transfer [2]. The authors speculated that this
decrease in maternal antibody transfer weakened the infants, making them more vulnerable to
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bacterial infections [2]. The authors of the above-cited studies showed that the efficacy of the
maternal antibody transfer in patients with PM varied according to antibody specificity [1–3].
Okoko et al. demonstrated that PM was associated with decreased anti-measles but not anti-
tetanus toxoid antibody transfer in the same cohort [2]. In contrast, Scott et al. showed that
PM was not associated with a lower anti-measles antibody level [4]. Deloron et al. observed no
difference in the transfer of antibodies targeting P. falciparum extracts according to placental
infection [5]. The effect of PM in specific antimalarial antibody transfer has not been
completely clarified.
The transport of IgG across the placenta is an active and selective process specifically medi-
ated by the neonatal Fc receptor (FcRn). One study revealed that high total and anti-measles
antibody levels in maternal peripheral blood were associated with reduced efficacy of specific
antibody transfer [6]. Saturation of the limited number of FcRn receptors on syncytiotropho-
blasts could be generated by high maternal IgG levels [7–9] and may therefore introduce a bias
in the analysis of PM’s effect on the efficacy of maternal-specific antibody transfer. Maternal
hypergammaglobulinemia is thus an essential factor to consider [1–3], and it was subsequently
determined and introduced in the analyses of the present study.
Few studies have investigated the role of transferred maternal antibodies on infants’ clinical
protection from malaria. Wilson et al. showed that functional anti-malaria antibodies crossed
the placenta, by assessing their functionality using the parasite growth inhibition assay [10].
However, another study showed a positive association between maternal antibody transfer and
malaria incidence in the 1st year of life [11]. Obviously, the mechanisms determining maternal
antibody transfer and its impact on infants’malaria infections remain unclear.
In the present study, we investigated serum reactivity against immunogenic antigens from
P. falciparum blood stages representing promising vaccine candidates—Apical Membrane
Antigen 1 (AMA1), Merozoite Surface Protein (MSP) 1–19, MSP2 (two allelic families: 3D7
and FC27), MSP3 and Glutamate-Rich Protein (GLURP, two regions: R0 and R2)–to highlight
the effect of PM in specific antimalarial antibody transfer, considering IgG specificity and
maternal hypergammaglobulinemia. The present study also investigated whether lower mater-
nal antibody transfer has consequences on infant health.
Material and Methods
Study design and sample collection
The study took place from June 2007 to January 2010 in Southern Benin (Tori Bossito district).
A weekly follow-up of 535 infants from birth to 18 months is detailed in a previous publication
[12]. The present work focused on the first 6-month period. Maternal circulating blood (CIRC)
and cord blood (CORD) samples were collected in Vacutainer1 EDTA (Ethylene diaminete-
traacetic acid) tubes at delivery and placental blood smears (from the maternal side of the pla-
centa) were made. Plasma was stored at −80°C. Infections were defined as any febrile event
(37.5°C) and malaria infection was defined as a febrile event with a positive rapid diagnostic
test or a positive thick blood smear. Symptomatic malaria infections were treated with arte-
mether/lumefantrine combination therapy, as per the National Malaria Control Program
(Benin) recommendations.
Data collection
The following data were collected: gestational age (estimated using the Ballard method [13],
gravidity (primigravid/multigravid), maternal age, maternal weight before delivery, low infant
birth weight (defined as a birth weight2500 g, [14]) and presence/absence of PM (defined by
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the presence of asexual forms of P. falciparum in thick placental smears). Table 1 shows a sum-
mary of these variables, according to presence/absence of PM.
P. falciparum recombinant antigens
MSP1-19 (Uganda-Palo-Alto strain) and MSP3 (F32 strain) were produced at the Pasteur
Institute (Paris, France). MSP2 (3D7 and FC27) were donated by collaborators from La Trobe
University (Melbourne, Australia). GLURP-R0 (F32 strain) and GLURP-R2 (F32 strain) were
produced by the Infection-Immunity Department of the Statens Serum Institute of Copenha-
gen (Denmark) and AMA1 was donated by the Biomedical Primate Research Centre (Rijswijk,
The Netherlands). All recombinant proteins were expressed in Escherichia coli except AMA1,
in Pichia pastoris.
Measurement of antibodies against P. falciparum recombinant antigens
Enzyme-Linked ImmunoSorbent Assay (ELISA) [15,16] was performed to assess malaria anti-
body concentrations; Afro Immuno Assay (AIA) protocols were followed that are developed to
standardize methods for evaluating malaria vaccines and sponsored by the African Malaria
Network Trust (AMANET [www.amanet-trust.org]). Briefly, standard curves were established
using purified human IgG (Binding Site, France) to determine the concentration of specific
antibodies. Each point was tested in duplicate.
Specific and total IgG were measured using recombinant proteins diluted in phosphate-
buffered saline (PBS) for specific IgG or an anti-human IgG (Fab-specific, Sigma Aldrich,
France) diluted in carbonate buffer for total IgG, both were coated at 0.1-μg/well on MaxiSorp
Nunc plates (Thermo Fisher Scientific, Denmark) and blocked with 3% powdered milk, 0.1%
Tween, 20 PBS. Maternal and cord blood samples were diluted at 1:200 for all IgG-specific,
recombinant proteins except for AMA1 (1:2,000) and total IgG (1:1,000,000). An anti-human
IgG coupled with peroxidase (1:3,000, Caltag, UK) was used to reveal the reaction with TMB
One (3, 30, 5, 50-tetramethylbenzidine, Mast Diagnostic, France). Plates were read at 450 nm.
Management of ELISA data
ELISA optical densities (OD) were analyzed with ADAMSEL FLP b039 software (http://www.
emvda.org/portfolio/project-index/optimalvac-project-completed), to determine antibody
Table 1. Characteristics of the population group.
Variables n (%) No placental malaria (n = 481) With placental malaria (n = 54) p-value
Hypergammaglobulinemiaa < 16 g.L-1 366 (68.4) 329 (89.9) 37 (10.1) 0.986
 16 g.L-1 169 (31.6) 152 (89.9) 17 (10.1)
Graviditya primigravid 82 (15.3) 67 (81.7) 15 (18.3) 0.007
multigravid 453 (84.7) 414 (91.4) 39 (8.6)
Mother's weight (kilograms)b 535 (100) 61.8 [47.5;76.1] 57.9 [51.3;64.5] 0.053
Mother's age (years)b 535 (100) 27.7 [22.2;33.2] 25.6 [19.5;31.6] 0.007
Low birth weight (grams)a < 2500 48 (9.0) 40 (83.3) 8 (16.7) 0.113
 2500 487 (91.0) 441 (90.6) 46 (9.4)
Gestational age (weeks)b 535 (100) 38.5 [36.7;40.3] 38.3 [36.5;40.1] 0.437
a: Chi2 test;
b: Student unpaired t-test;
percentages are written in parentheses; standard deviations are written in square brackets; in bold: p<0.05.
doi:10.1371/journal.pone.0145464.t001
Placental Malaria Decreases Maternal Antibody Transfer
PLOS ONE | DOI:10.1371/journal.pone.0145464 December 23, 2015 3 / 11
concentrations (μg/mL). Discordant duplicates (with a variation coefficient>15%) were re-
tested.
A stochastic expectation maximization algorithm [17], already applied to ELISA analyses
[18], was used to impute data in cases where the OD was below detection thresholds or was
oversaturated [referred to as “Low” and “High” concentration values (μg/mL), respectively].
Placental antibody transfer
Prior to analyses, antibody levels were log-transformed (natural logarithm (ln)). Placental anti-
body transfer was defined as the natural logarithm of the ratio between neonatal and maternal
antibody levels expressed in μg/mL (ln (CORD/CIRC)).
Statistical analyses
For quantitative variables, means were compared using a Student unpaired t-test. A chi-
squared test was used to compare categorical variables (Table 1). Linear regression was used
for both univariate and multivariate analyses of the antibody transfer. Analyses were adjusted
according to maternal-specific IgG levels, hypergammaglobulinemia (defined as total IgG16
g.L−1 [1–3]) and the variables listed in the “Data collection” section. A logistic regression was
used for both univariate and multivariate analyses of the impact of the maternal antibody
transfer on infant infections. A multinomial logistic model investigated the effect of maternal
antibody transfer on malaria or non-malaria infections in the infants. Multivariate analysis was
performed, including the variables with p0.20 in the univariate step. Statistical significance
was set at p<0.05 in the linear regression analysis and at p<0.01 in the logistic regression. All
statistical analyses were performed using Stata, version 13.0 (StatCorp LP, College Station, TX,
USA).
Ethics
This study protocol was approved by the institutional Ethics Committee of the Faculté des Sci-
ences de la Santé from the Université d’Abomey-Calavi in Benin and the Comité Consultatif de
Déontologie et d’Ethique from the French Institut de Recherche pour le Développement. The
nature of the project was explained in detail to the participants and informed consent was
obtained from the women included in the study. All women signed informed consent before
enrollment (which also included their children) and could withdraw from the study at any
time [12].
Results
Description of the cohort
Ten percent of the pregnant women enrolled had an active placental infection at delivery
(n = 54). Maternal hypergammaglobulinemia, maternal weight, infant gestational age and low
infant birth weight were not affected by PM. The risk of PM was higher in primigravid mothers
and in younger mothers (Table 1).
IgG levels in maternal peripheral blood and cord blood
Maternal-specific IgG levels were higher at delivery in women presenting with PM than those
without PM. This difference was significant for AMA1, MSP1-19, MSP2-3D7 and MSP3 (all
p<0.049; Table 2). Interestingly, most antimalarial IgG levels in cord blood were similar,
whether or not the mother presented with PM at delivery, with the exception of higher IgG lev-
els to MSP2-FC27 (p = 0.035) and lower total IgG levels (p = 0.026) in PM infection (Table 2).
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Placental transfer of malaria-specific IgG
Placental transfer of malaria-specific IgG was significantly reduced in the presence of PM (all
p<0.019) for all antigens except MSP2-FC27 and total IgG (Table 2, Fig 1). PM and maternal-
specific IgG levels were the two main factors consistently associated with the reduction of pla-
cental transfer, except MSP2 (PM) and total IgG (maternal IgG levels) (Table 3). Maternal
hypergammaglobulinemia impaired the transfer of some specific IgG (directed to AMA1,
MSP2-FC27 and GLURP-R2) and total IgG from the mother to the fetus (Table 3). Other fac-
tors were occasionally associated with the CORD/CIRC ratio: the transfer of IgG specific to
MSP2-3D7 was positively associated with gestational age, maternal age and maternal-specific
IgG levels. The transfer of MSP1 was negatively associated with gestational age.
Maternal antibody transfer and infant infections
Maternal age was negatively associated with the presence of a febrile infection (malaria or non-
malaria) in 6-month-old infants (Table 4). Given the number of tests, these results must be
carefully interpreted and therefore differences with p<0.01 were considered significant. In this
context, hypergammaglobulinemia and maternal IgG levels to MSP2-FC27 tended to be
Table 2. Cord blood andmaternal specific antibody levels as well as their ratio, according to placental malaria infection.
Antigen Bloodcompartment IgG levels b p-value
No placental infection (n = 481) With placental infection (n = 54)
AMA1 CIRC a 577.81 [573.68;581.93] 897.33 [893.61;901.04] 0.03
CORD a 518.62 [514.95;522.28] 667.16 [663.44;670.87] 0.178
(CORD/CIRC) a 0.89 [-0.69;2.46] 0.74 [-0.87;2.36] 0.007
MSP1-19 CIRC 29.91 [22.65;37.17] 51.50 [46.41;56.58] 0.053
CORD 22.53 [16.55;28.50] 27.37 [22.83;31.90] 0.442
(CORD/CIRC) 0.76 [-1.03;2.55] 0.53 [-1.35;2.41] <0.001
MSP2-3D7 CIRC 84.64 [80.32;88.96] 130.34 [126.52;134.16] 0.039
CORD 47.16 [43.35;50.97] 58.23 [54.91;61.56] 0.268
(CORD/CIRC) 1.79 [-0.12;3.71] 2.24 [0.34;4.14] 0.018
MSP2-FC27 CIRC 50.09 [46.81;53.37] 65.79 [62.90;68.69] 0.107
CORD 94.01 [89.70;98.32] 145.62 [142.07;149.17] 0.035
(CORD/CIRC) 1.88 [-0.08;3.83] 2.21 [0.32;4.11] 0.085
MSP3 CIRC 8.17 [2.50;13.83] 13.99 [8.41;19.59] 0.031
CORD 5.50 [0.42;10.59] 7.33 [2.50;12.15] 0.22
(CORD/CIRC) 0.67 [-1.01;2.35] 0.52 [-1.11;2.15] 0.001
GLURP-R0 CIRC 5.49 [0.63;10.36] 7.41 [2.31;12.51] 0.189
CORD 3.36 [-1.07;7.80] 3.46 [-1.17;8.09] 0.894
(CORD/CIRC) 0.61 [-1.11;2.33] 0.47 [-1.13;2.06] 0.001
GLURP-R2 CIRC 36.97 [33.04;40.90] 54.62 [49.45;59.78] 0.052
CORD 21.47 [17.89;25.06] 22.70 [18.73;26.68] 0.763
(CORD/CIRC) 0.57 [-1.15;2.29] 0.42 [-1.67;2.51] <0.001
Nonspeciﬁc total IgG CIRC 12096.24 [12093.78;12098.71] 10943.12 [10940.42;10945.81] 0.444
CORD 10703.50 [10701.21;10705.78] 8177.39 [8174.82;8179.97] 0.026
(CORD/CIRC) 0.88 [-1.21;2.98] 0.75 [-1.13;2.63] 0.105
a: CIRC: maternal peripheral blood at delivery; CORD: cord blood, (CORD/CIRC): ratio representing the transfer of maternal IgG to the neonate at birth;
b: geometric mean [95% conﬁdence interval] of the IgG concentrations;
Student’s unpaired t-test was performed; n: effective; in bold: p< 0.05.
doi:10.1371/journal.pone.0145464.t002
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Fig 1. Cord-to-mother IgG transfer according to placental malaria.CIRC: maternal peripheral blood at
delivery; CORD: cord blood, ln(CORD/CIRC): ratio representing the transfer of maternal IgG to the neonate at
birth; * <0.05; **0.01; ***0.001.
doi:10.1371/journal.pone.0145464.g001
Table 3. Linear regression model showing the factors involved in impairedmaternal IgG transfer.
AMA1 MSP1 MSP2-3D7
Variables coeffa p-value coeff p-value coeff p-value
Placental malaria -0.126 [-0.245;-0.006] 0.039 -0.293 [-0.44;-0.145] <0.001
Gestational age -0.029 [-0.054;-0.004] 0.023 0.265 [0.096;0.433] 0.002
Maternal age 0.016 [0.005;0.027] 0.004
Maternal-speciﬁc IgG -0.118 [-0.144;-0.092] <0.001 -0.135 [-0.158;-0.112] <0.001 0.187 [0.152;0.221] <0.001
Hypergammaglobulinemia -0.097 [-0.176;-0.018] 0.016
MSP2-FC27 MSP3 GLURP-R0
Variables coeff p-value coeff p-value coeff p-value
Placental malaria -0.188 [-0.324;-0.051] 0.007 -0.232 [-0.375;-0.089] 0.002
Gestational age
Maternal age
Maternal-speciﬁc IgG 0.084 [0.037;0.132] <0.001 -0.107 [-0.13;-0.083] <0.001 -0.113 [-0.141;-0.086] <0.001
Hypergammaglobulinemia 0.2 [0.08;0.319] 0.001
GLURP-R2 Total IgG
Variables coeff p-value coeff p-value
Placental malaria -0.252 [-0.398;-0.106] 0.001
Gestational age
Maternal age
Maternal-speciﬁc IgG -0.153 [-0.185;-0.121] <0.001
Hypergammaglobulinemia -0.157 [-0.253;-0.061] 0.001 -0.581 [-0.705;-0.458] <0.001
a: coeff [95% conﬁdence interval]: coefﬁcient determined by the linear model. A positive (negative) coefﬁcient corresponds to a positive (negative)
association between two variables.
doi:10.1371/journal.pone.0145464.t003
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negatively and positively associated with the occurrence of an infant infection, respectively.
Neither the transfer of other malaria-specific IgG nor of total IgG was associated with infection
incidence. Placental malaria was not associated with 6-month-old infant infections. When
infections were split into non-malaria (mainly gastrointestinal (31.6%) and respiratory (65.2%)
febrile syndromes [19]) and malaria, only maternal age was negatively associated with the pres-
ence of a malaria infection in infants less than 6 months of age (Table 5).
Discussion
This study aimed to describe the neonatal transfer of maternal antibodies specific to malaria
blood-stage antigens. It showed that i) PM was associated with a lower CORD/CIRC ratio of
malaria-specific IgG, ii) maternal IgG transfer differed depending on malaria antibody specific-
ity, iii) cord blood antimalarial IgG levels were equivalent after adjustment for hypergamma-
globulinemia and PM and iv) older maternal age was associated with fewer malaria infections
in infants.
One limitation of this study may be the definition of PM based on light microscopy. As anti-
body transfer increases at the end of pregnancy, an active placental infection could reinforce
the strong association with lower antibody transfer. Using more sensitive methods such as his-
topathology or molecular biology, which can determine low parasitemia in placental infections,
could refine the results. However, a recent study in which placental infection was defined by
light microscopy, quantitative PCR or histological examination provided results comparable to
those in this study [11].
The present study confirmed that hypergammaglobulinemia or high levels of specific anti-
bodies in maternal blood were associated with a decrease in the CORD/CIRC ratio after adjust-
ment for PM. Regarding the mechanism of placental antibody transfer, it has been suggested
that the FcRn expressed by syncytiotrophoblasts in placenta binds IgG with subsequent inter-
nalization of the FcRn-IgG complex in endosomal compartments and release of maternal IgG
Table 4. Logistic regression model showing the factors involved in infant infections.
Factors coeff a p-value
Hypergammaglobulinemia -0.457 [-0.849;-0.064] 0.023
Maternal age -0.049 [-0.082;-0.017] 0.003
Maternal IgG to MSP2-FC27 0.291 [0.011;0.570] 0.042
a: coeff [95% conﬁdence interval]: coefﬁcient determined by the logistic model. A positive (negative) coefﬁcient corresponds to a positive (negative)
association between two variables; in bold: p<0.01.
doi:10.1371/journal.pone.0145464.t004
Table 5. Multinomial logistic regression model showing the factors involved in infant malaria/non-malaria infections.
Infections Factors coeff a p-value
Non-malaria infection Hypergammaglobulinemia -0.474 [-0.910;-0.037] 0.033
Maternal age -0.041 [-0.076;-0.005] 0.025
Maternal IgG to MSP2-FC27 0.314 [0.008;0.620] 0.044
Malaria infection Hypergammaglobulinemia -0.413 [-1.024;-0.198] 0.185
Maternal age -0.072 [-0.122;-0.021] 0.005
Maternal IgG to MSP2-FC27 0.229 [-0.200;0.658] 0.296
a: coeff [95% conﬁdence interval]: coefﬁcient determined by the logistic model. A positive (negative) coefﬁcient corresponds to a positive (negative)
association between two variables; in bold: p<0.01.
doi:10.1371/journal.pone.0145464.t005
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in fetal circulation [20,21]. The amount of IgG transmitted depends on the number of cell-sur-
face receptors because unbound IgG are digested by lysosomal enzymes inside the vesicles, as
has been suggested [22]. Some IgG may also be retained in the maternal compartment due to
host differences in the functionality and/or density of the FcRn [23] regardless of malaria. We
also hypothesize that the parasitized erythrocytes could adhere to syncytiotrophoblast vesicles,
where the IgG binding site is assumed to be [21,24], physically impairing IgG capture from the
maternal compartment. To our knowledge, no evidence exists to prove that the receptors of
parasitized erythrocytes (chondroitin sulfate A) and vesicles are located at different parts of the
syncytiotrophoblast. Finally, maternal IgG could be monopolized in the intervillous space to
combat a local malaria infection, contributing to decreasing transplacental IgG transfer.
Several studies, including one that uses the same cohort as the current study [25–29], estab-
lished that infants born to mothers with PM detected at delivery were more susceptible to
malaria infections in infancy than others. This occurred independently of similar specific anti-
body levels measured in the cord blood of infants born to infected and noninfected mothers
[14], suggesting that the PM-associated decrease of maternal IgG transfer may not explain the
higher risk of malaria infection observed in these infants and may instead be a marker of
maternal exposure to parasites [11].
These results show that maternal IgG to MSP2-FC27 tended to be positively related to the
number of non-malaria infections in infants under 6 months old, independently of PM. Given
the few tests performed, these results should be interpreted with caution. However, a positive
association between the transfer of IgG1 to AMA1 as well as IgG to parasite lysate and malaria
incidence during the 1st year of life was also observed in another study [11]. Similarly, maternal
IgG levels to variant surface antigens expressed by chondroitin sulfate A-adhering parasites
were negatively correlated to time before the first parasitemia in Cameroonian infants and pos-
itively correlated to mean parasite density, suggesting a nonprotective role [30]. Lastly, a Gha-
nian study conducted showed that high maternal IgG levels to MSP1-19, MSP2-FC27 and
Pf155/RESA were associated with a higher risk of infant infection [31].
Based on these studies and the present work, it seems that maternal IgG specific to malaria
is a marker of maternal exposure to P. falciparum. Several studies have already shown that
maternal antibodies can inhibit infant responses to different diseases, such as measles or teta-
nus [32–34]. How maternal antimalarial IgG influences malaria or non-malaria infection inci-
dence in infants remains unclear and needs further investigation.
Interestingly, we found that the older a pregnant woman was, lower the number of malaria
infections of her infant was, suggesting that effective maternal immunity acquired with age can
be transmitted to offspring. This raises questions on how the immune response evolves in preg-
nancy and we speculate on the role of one or several maternal molecules. These molecules
must i) be produced differently with age and ii) have the property of either crossing the placen-
tal barrier or inducing, by their presence at the maternal—fetal interface, tolerance/protection
against malaria infections during the first 6 months of life. Cytokines and antibodies are two
types of molecules with these properties, in agreement with a definition of transplacental
immune regulation formulated by Santner et al. as “the concept that during pregnancy, signifi-
cant cross-talk occurs between the maternal and fetal immune system with potential long-term
effects for both the mother and child” [35]. Few clues are available in the literature, particularly
IL-10, which is a cytokine with known immunomodulatory properties [36]. Newborns born to
young mothers have been shown to present higher fetal plasma IL-10 levels than newborns
born to older mothers [37]. Similarly, maternal IL-10 levels have been negatively associated
with parity [38], which may reasonably be related to maternal age. Evidence for alignment
between maternal and fetal cellular immunity has been provided, implying T regulatory cells
and IL-10 concentrations [35]. Lastly, higher IL-10 levels were found in malaria-exposed, non-
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sensitized newborns compared to sensitized, unexposed newborns, with this phenotype persist-
ing during childhood [28]. Based on these studies, we hypothesize that IL-10 levels in the sera
of mother and her fetus may act as a molecular contributor increasing protection of the infant
against malaria infection depending on maternal age.
This study did not explore the functionality of maternal antibodies, possibly one of the
immune parameters evolving with maternal age (in that the total IgG quantity was not associ-
ated with maternal age resulting from a linear regression coefficient = −0.0038; p = 0.598).
Transfer of functional malaria antibodies to the fetus has been demonstrated by measuring
their ability to inhibit parasite growth in cord blood and infant blood, but the experiment did
not consider maternal blood or maternal age [10]. In fact, the sole antibodies that evolve in a
parity- (and therefore age-) dependent manner in malaria-endemic areas are those directed to
the variant surface antigen responsible for placental adhesion of infected erythrocytes, repre-
sented by the VAR2CSA variant of the P. falciparum erythrocyte membrane protein 1
(PfEMP1) antigen [39–41]. Maternal transfer of functional antibodies or anti-VAR2CSA anti-
bodies to the fetus and the cytokine levels in fetal plasma depending on maternal age should be
further investigated to provide new clues on whether or not maternal age plays a protective
role in infant health.
In conclusion, This study confirmed lower maternal transfer of IgG directed to several asex-
ual stages of P. falciparum in placental malaria. Why the degree of maternal antimalarial IgG
transfer was not related to the incidence of febrile infections in infants’ first 6 months of life,
but instead maternal age, needs further investigation.
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